Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience

被引：169

作者：

Medeiros, Bruno C. ^{[1
]}

Othus, Megan ^{[2
,3
]}

Fang, Min ^{[3
,4
,5
]}

Roulston, Diane ^{[6
]}

Appelbaum, Frederick R. ^{[3
,5
]}

机构：

[1] Stanford Univ, Stanford, CA 94305 USA

[2] SW Oncol Grp, Ctr Stat, Seattle, WA USA

[3] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA

[4] Seattle Canc Care Alliance, Seattle, WA USA

[5] Univ Washington, Seattle, WA 98195 USA

[6] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA

来源：

BLOOD | 2010年 / 116卷 / 13期

关键词：

CHEMOTHERAPY; DAUNORUBICIN; CYTARABINE; THERAPY;

D O I：

10.1182/blood-2010-02-270330

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Monosomal karyotype (MK), defined as 2 or more monosomies, or a single monosomy in the presence of structural abnormalities, has recently been reported as identifying a distinct subset of acute myeloid leukemia (AML) patients with an extremely poor prognosis. In an effort to confirm this observation, we analyzed the prognostic impact of MK in 1344 AML patients between the ages of 16 and 88 years treated on Southwest Oncology Group protocols. MK was found in 176 (13%) patients. The proportion of patients with MK increased with age, being present in 4% of patients age 30 or younger, but in 20% of those over age 60. Ninety-eight percent of MK cases were within the unfavorable cytogenetic risk category and comprised 40% of this group. The complete remission rate in patients with unfavorable cytogenetics without MK was 34% versus 18% with MK (P < .01). The 4-year overall survival of patients with unfavorable cytogenetics but without MK was 13% in contrast to a 4-year survival of only 3% with MK (P < .01). Thus, MK defines a sizeable subset of patients with unfavorable cytogenetics who have a particularly poor prognosis. (Blood. 2010;116(13):2224-2228)

引用

页码：2224 / 2228

页数：5

共 19 条

[1] Monosomy Karyotype in Acute Myeloid Leukemia Predicts Adverse Treatment Outcome with Low Complete Remission Rate and Worse Event-Free and Overall Survival, and Associates with High Functional Activity of Multidrug Resistance (MDR). [J].

Ahn, Hee Kyung ;

Kim, Dong Hwan ;

Park, Silvia ;

Jang, Jun Ho ;

Kim, Kihyun ;

Kim, Hee-Jin ;

Kim, Sun-Hee ;

Jung, Chul Won .

BLOOD, 2009, 114 (22) :1210-1210

[2] Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study [J].

Anderson, JE ;

Kopecky, KJ ;

Willman, CL ;

Head, D ;

O'Donnell, MR ;

Luthardt, FW ;

Norwood, TH ;

Chen, IM ;

Balcerzak, SP ;

Johnson, DB ;

Appelbaum, FR .

BLOOD, 2002, 100 (12) :3869-3876

[3] Monosomal karyotype in acute myeloid leukemia:: A better indicator of poor prognosis than a complex karyotype [J].

Breems, Dimitri A. ;

Van Putten, Wim L. J. ;

De Greef, Georgine E. ;

Van Zelderen-Bhola, Shama L. ;

Gerssen-Schoorl, Klasien B. J. ;

Mellink, Clemens H. M. ;

Nieuwint, Aggie ;

Jotterand, Martine ;

Hagemeijer, Anne ;

Beverloo, H. Berna ;

Lowenberg, Bob .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (29) :4791-4797

[4] Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia:: results from Cancer and Leukemia Group B (CALGB 8461) [J].

Byrd, JC ;

Mrózek, K ;

Dodge, RK ;

Carroll, AJ ;

Edwards, CG ;

Arthur, DC ;

Pettenati, MJ ;

Patil, SR ;

Rao, KW ;

Watson, MS ;

Koduru, PRK ;

Moore, JO ;

Stone, RM ;

Mayer, RJ ;

Feldman, EJ ;

Davey, FR ;

Schiffer, CA ;

Larson, RA ;

Bloomfield, CD .

BLOOD, 2002, 100 (13) :4325-4336

[5] Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission [J].

Cassileth, PA ;

Harrington, DP ;

Appelbaum, FR ;

Lazarus, HM ;

Rowe, JM ;

Paietta, E ;

Willman, C ;

Hurd, DD ;

Bennett, JM ;

Blume, KG ;

Head, DR ;

Wiernik, PH .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (23) :1649-1656

[6] Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia [J].

Chauncey, Thomas R. ;

Gundacker, Holly ;

Shadman, Mazyar ;

List, Alan F. ;

Dakhil, Shaker R. ;

Erba, Harry P. ;

Slovak, Marilyn L. ;

Chen, I-Ming ;

Willman, Cheryl L. ;

Kopecky, Kenneth J. ;

Appelbaum, Frederick R. .

BRITISH JOURNAL OF HAEMATOLOGY, 2010, 148 (01) :48-58

[7]

COX DR, 1972, J R STAT SOC B, V34, P187

[8] A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: A Southwest Oncology Group study (9031) [J].

Godwin, JE ;

Kopecky, KJ ;

Head, DR ;

Willman, CL ;

Leith, CP ;

Hynes, HE ;

Balcerzak, SP ;

Appelbaum, FR .

BLOOD, 1998, 91 (10) :3607-3615

[9] Prognostic Value of Monosomal Karyotype in Patients with Primary Acute Myeloid Leukemia On Behalf of Spanish CETLAM Group. [J].

Granada, Isabel ;

Brunet, Salut ;

Hoyos, Montserrat ;

Costa, Dolors ;

Aventin, Anna ;

Marugan, Isabel ;

Vallespi, Teresa ;

Barnues, Marta ;

Duarte, J. J. ;

Sole, Francesc ;

Teixido, Montserrat ;

Mascaro, M. ;

Llorente, Andreu ;

Guardia, Ramon ;

Tormo, Mar ;

Duarte, Rafael F. ;

Milla, Fuensanta ;

Esteve, Jordi ;

Ribera, Josep-Maria ;

Sierra, Jordi .

BLOOD, 2009, 114 (22) :416-416

[10] The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial [J].

Grimwade, D ;

Walker, H ;

Oliver, F ;

Wheatley, K ;

Harrison, C ;

Harrison, G ;

Rees, J ;

Hann, I ;

Stevens, R ;

Burnett, A ;

Goldstone, A .

BLOOD, 1998, 92 (07) :2322-2333

← 1 2 →